Osokkanatulang Deaths occurred in 89 patients talenglele
vietnam
Entertainment
+916127027194
frenzinaomi@gmail.com
Added on 21 Mar 2025
2038 Jewell Road
Business Description
“This prespecified long-term follow-up analysis provides additional support for the neoadjuvant therapy paradigm by showing that adjuvant T-DM1 also provided a significant improvement in overall survival and no evidence of long-term safety issues,” wrote KATHERINE investigators in The New England Journal of Medicine.
Patients enrolled in the phase 3, open-label trial continued to see an improvement in invasive disease-free survival with T-DM1 vs trastuzumab at a median follow-up of 8.4 years (unstratified HR = 0.54; 95% CI, 0.44-0.66). Particularly, 19.7% of patients in the T-DM1 group and 32.2% of patients in the trastuzumab group experienced invasive disease events or death.
Seven-year invasive disease-free survival was achieved in 80.8% of patients treated with T-DM1 and 67.1% of patients on trastuzumab (difference, 13.7 percentage points).
The trial included patients with HER2-positive early breast cancer who had received neoadjuvant treatment, which included a taxane-based chemotherapy and/or trastuzumab, and had residual invasive cancer in the breast or resected axillary nodes. Patients were randomly assigned to receive either T-DM1 (n = 743) or trastuzumab (n = 743). Patients were stratified by clinical stage, hormone-receptor status, preoperative HER2-directed therapy, and pathological nodal status after neoadjuvant therapy.
T-DM1 significantly reduced the risk for death compared with trastuzumab (unstratified HR = 0.66; 95% CI, 0.51-0.87; P = .003). Seven-year overall survival for the T-DM1 and trastuzumab groups were 89.1% and 84.4%, respectively (difference, 4.7 percentage points). As of the trial’s cutoff date of October 5, 2023, 70.1% of patients assigned T-DM1 and 62.0% of patients assigned trastuzumab were alive and still in the trial.
Deaths occurred in 89 patients (12.0%) in the T-DM1 group and 126 patients (17.0%) in the trastuzumab group. Of these deaths, 70 (79%) and 108 (86%) patients, respectively, died from breast cancer.
https://popl.co/profile/Ukib4YXW/dash
https://popl.co/profile/urtYnNEQ/dash
https://popl.co/profile/YW1JrpmP/dash
https://popl.co/profile/4e6JMflw/dash
https://popl.co/profile/C4pxHCfr/dash
https://popl.co/profile/8a81L4Ix/dash
https://popl.co/profile/4dyLV11p/dash
https://popl.co/profile/TMzT4Yqb/dash
https://popl.co/profile/cOJnc9Z2/dash
https://popl.co/profile/8vPK2Xi6/dash
https://popl.co/profile/xxu7ad7Q/dash
https://popl.co/profile/IfJzDadm/dash
https://popl.co/profile/ovkcKjYU/dash
https://popl.co/profile/btatoBuw/dash
https://popl.co/profile/ia4i3QHZ/dash
https://popl.co/profile/ZOg9U4Ln/dash
https://popl.co/profile/N04QaYIs/dash
https://popl.co/profile/SppiKa6L/dash
https://popl.co/profile/mfJekr4v/dash
https://popl.co/profile/sJEygXHC/dash
https://popl.co/profile/87qT0tAb/dash
https://popl.co/profile/68Kgd1xZ/dash
https://popl.co/profile/MgIdK8Y5/dash
https://popl.co/profile/KFiCkeIj/dash
https://popl.co/profile/QmZixgc3/dash
https://papaly.com/categories/share?id=3b04a0c17a524f8d890886d49597bc40
https://pinshape.com/users/7440768-1hs30lot8ljdjhhghgg
https://fileforum.com/profile/gcxmx4cp14cscs
https://all4.vip/p/page/view-persons-profile?id=67931
